Drug class
The phrase "Antineoplastic - Anti-Programmed Death-(PD-1/L1) MC Antibody" represents a compendial and formulary drug classification used by standardized drug databases to group antineoplastic monoclonal antibodies that target the PD-1/PD-L1 checkpoint axis. Read more about Antineoplastic - Anti-Programmed Death-(PD-1/L1) MC Antibody
14 drugs in this class 11 manufacturers
The phrase "Antineoplastic - Anti-Programmed Death-(PD-1/L1) MC Antibody" represents a compendial and formulary drug classification used by standardized drug databases to group antineoplastic monoclonal antibodies that target the PD-1/PD-L1 checkpoint axis.
Clinically recognized as immune checkpoint inhibitors, these therapeutic antibodies bind directly to either programmed cell death protein 1 on T cells or programmed death-ligand 1 on tumor and immune-infiltrating cells.
By disrupting this inhibitory pathway, the agents overcome tumor-mediated immunosuppression and restore host T-cell–mediated antitumor immune responses.
Monoclonal antibodies in this therapeutic class are widely indicated across medical oncology for diverse malignancies, including non-small cell lung cancer, melanoma, renal cell carcinoma, urothelial carcinoma, and tumors displaying high microsatellite instability or mismatch repair deficiency.
The phrase "Antineoplastic - Anti-Programmed Death-(PD-1/L1) MC Antibody" represents a compendial and formulary drug classification used by standardized drug databases to group antineoplastic monoclonal antibodies that target the PD-1/PD-L1 checkpoint axis
The phrase "Antineoplastic - Anti-Programmed Death-(PD-1/L1) MC Antibody" represents a compendial and formulary drug classification used by standardized drug databases to group antineoplastic monoclonal antibodies that target the PD-1/PD-L1 checkpoint axis
Clinically recognized as immune checkpoint inhibitors, these therapeutic antibodies bind directly to either programmed cell death protein 1 on T cells or programmed death-ligand 1 on tumor and immune-infiltrating cells By disrupting this inhibitory pathway, the agents overcome tumor-mediated immunosuppression and restore host T-cell–mediated antitumor immune responses
Clinically recognized as immune checkpoint inhibitors, these therapeutic antibodies bind directly to either programmed cell death protein 1 on T cells or programmed death-ligand 1 on tumor and immune-infiltrating cells
By disrupting this inhibitory pathway, the agents overcome tumor-mediated immunosuppression and restore host T-cell–mediated antitumor immune responses
Monoclonal antibodies in this therapeutic class are widely indicated across medical oncology for diverse malignancies, including non-small cell lung cancer, melanoma, renal cell carcinoma, urothelial carcinoma, and tumors displaying high microsatellite instability or mismatch repair deficiency
Monoclonal antibodies in this therapeutic class are widely indicated across medical oncology for diverse malignancies, including non-small cell lung cancer, melanoma, renal cell carcinoma, urothelial carcinoma, and tumors displaying high microsatellite instability or mismatch repair deficiency
Following a drug class requires a free Physicians Office Resource account.
